AstraZeneca eyes first-line gMG market with self-administered gefurulimab
UK pharma major AstraZeneca (LSE: AZN) is preparing to advance gefurulimab as a potential new treatment for generalized myasthenia gravis, following positive results in a global Phase III trial that could pave the way for regulatory filings.
The investigational therapy, developed by AstraZeneca’s Alexion rare disease unit, met both its primary and all secondary endpoints in the PREVAIL study, which enrolled 260 adults living with a certain kind of gMG.
AstraZeneca said gefurulimab was well tolerated, with no new safety concerns emerging in the study. The company now plans to share the results with health authorities and present the data at an upcoming medical conference.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze